

Armando Tripodi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7948115/publications.pdf>

Version: 2024-02-01

192
papers

12,600
citations

36691

53
h-index

30277

107
g-index

198
all docs

198
docs citations

198
times ranked

10677
citing authors

#	ARTICLE	IF	CITATIONS
1	Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 39-47.	1.9	39
2	Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. <i>Biomedicines</i> , 2022, 10, 249.	1.4	16
3	Simvastatin Prevents Liver Microthrombosis and Sepsis Induced Coagulopathy in a Rat Model of Endotoxemia. <i>Cells</i> , 2022, 11, 1148.	1.8	7
4	Cirrhosis. What are all those factor VIII and protein C for?. <i>Journal of Hepatology</i> , 2022, , .	1.8	1
5	The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time. <i>Vascular Pharmacology</i> , 2022, 144, 106994.	1.0	0
6	Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding.. <i>Blood Transfusion</i> , 2022, , .	0.3	5
7	Impact of a commercially available <sc>DOAC</sc> absorbent on two integrated procedures for lupus anticoagulant detection in plasma containing argatroban. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	0.7	0
8	Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Societ� Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Societ� Italiana per lo Studio dell'Emostasi e della Trombosi (SISST). <i>Journal of Nephrology</i> , 2021, 34, 31-38.	0.9	6
9	Hemostatic alterations in COVID-19. <i>Haematologica</i> , 2021, 106, 1472-1475.	1.7	34
10	Relationship between thrombin generation parameters and prothrombin fragment 1�+�2 plasma levels. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e248-e251.	0.7	3
11	Anti-TNF-� Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1901-1908.	0.9	5
12	The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1116-1122.	1.9	66
13	Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1372-1378.	1.9	32
14	Pro-coagulant imbalance in patients with community acquired pneumonia assessed on admission and one month after hospital discharge. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1699-1708.	1.4	1
15	Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia. <i>Haematologica</i> , 2021, 106, 3021-3024.	1.7	8
16	Diagnostic Challenges on the Laboratory Detection of Lupus Anticoagulant. <i>Biomedicines</i> , 2021, 9, 844.	1.4	5
17	Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection. <i>Thrombosis Research</i> , 2021, 204, 32-39.	0.8	11
18	No changes of parameters nor coagulation activation in healthy subjects vaccinated for SARS-Cov-2. <i>Thrombosis Update</i> , 2021, 4, 100059.	0.4	6

#	ARTICLE	IF	CITATIONS
19	Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 365-371.	1.4	11
20	Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1660-e1672.	1.8	7
21	Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISSET). <i>Blood Transfusion</i> , 2021, 19, 14-23.	0.3	4
22	Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. <i>Journal of Hepatology</i> , 2020, 72, 85-94.	1.8	68
23	Procoagulant imbalance in preterm neonates detected by thrombin generation procedures. <i>Thrombosis Research</i> , 2020, 185, 96-101.	0.8	12
24	Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 413-419.	1.0	2
25	Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISSET. <i>Haemophilia</i> , 2020, 26, 937-945.	1.0	17
26	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2828-2839.	1.9	211
27	Usefulness of Thrombin Generation. <i>Hamostaseologie</i> , 2020, 40, 509-514.	0.9	11
28	Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease. <i>Frontiers in Pediatrics</i> , 2020, 8, 510.	0.9	4
29	Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3117-3118.	1.9	6
30	Letter to the Editor: Thromboelastography-Guided Blood Product Transfusion in Cirrhosis With Coagulopathy: Real Saving or Just Less Waste?. <i>Hepatology</i> , 2020, 72, 1158-1159.	3.6	2
31	Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study. <i>International Journal of Laboratory Hematology</i> , 2020, 42, e128-e131.	0.7	2
32	Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review. <i>European Journal of Haematology</i> , 2020, 104, 519-525.	1.1	15
33	Effect of different methods for outlier detection and rejection when calculating cut off values for diagnosis of lupus anticoagulants. <i>Thrombosis Research</i> , 2020, 190, 20-25.	0.8	4
34	Is placental blood a reliable source for the evaluation of neonatal hemostasis at birth?. <i>Transfusion</i> , 2020, 60, 1069-1077.	0.8	11
35	Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1569-1575.	1.9	76
36	Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1738-1742.	1.9	1,070

#	ARTICLE	IF	CITATIONS
37	Thromboelastographic profiles of healthy very low birthweight infants serially during their first month. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2020, 105, 412-418.	1.4	17
38	COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISSET). <i>Blood Transfusion</i> , 2020, 18, 167-169.	0.3	247
39	Thrombin generation: a global coagulation procedure to investigate hypo- and hyper-coagulability. <i>Haematologica</i> , 2020, 105, 2196-2199.	1.7	10
40	Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial". <i>Blood Transfusion</i> , 2020, 18, 239-240.	0.3	2
41	Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISSET. <i>Blood Transfusion</i> , 2020, 18, 478-485.	0.3	2
42	Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis. <i>Vascular Pharmacology</i> , 2019, 113, 92-93.	1.0	5
43	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. <i>Liver International</i> , 2019, 39, 2309-2316.	1.9	8
44	Body mass index reduction improves the baseline procoagulant imbalance of obese subjects. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 52-60.	1.0	8
45	Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. <i>Gastroenterology</i> , 2019, 156, 1582-1599.e1.	0.6	230
46	Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study. <i>Thrombosis Research</i> , 2019, 174, 84-87.	0.8	4
47	Advances in the Treatment of Hemophilia: Implications for Laboratory Testing. <i>Clinical Chemistry</i> , 2019, 65, 254-262.	1.5	23
48	Response to Portal vein thrombosis after hepatitis C eradication with direct acting antiviral therapy.. <i>Liver International</i> , 2018, 38, 186-186.	1.9	0
49	The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. <i>Internal and Emergency Medicine</i> , 2018, 13, 1029-1036.	1.0	27
50	Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. <i>Haematologica</i> , 2018, 103, e315-e317.	1.7	34
51	Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1146-1152.e4.	2.4	77
52	The intra-assay reproducibility of thromboelastography in very low birth weight infants. <i>Early Human Development</i> , 2018, 127, 48-52.	0.8	13
53	Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISSET, FCSA, SIBioC and SIPMeL. <i>Blood Transfusion</i> , 2018, 16, 462-470.	0.3	54
54	Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. <i>Liver International</i> , 2017, 37, 1295-1303.	1.9	18

#	ARTICLE	IF	CITATIONS
55	Hemostasis in Acute and Chronic Liver Disease. <i>Seminars in Liver Disease</i> , 2017, 37, 028-032.	1.8	29
56	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. <i>Internal and Emergency Medicine</i> , 2017, 12, 1109-1119.	1.0	30
57	Critical laboratory values in hemostasis: toward consensus. <i>Annals of Medicine</i> , 2017, 49, 455-461.	1.5	20
58	Commentary. <i>Clinical Chemistry</i> , 2017, 63, 1445-1446.	1.5	0
59	Lupus Anticoagulant Testing: Activated Partial Thromboplastin Time (APTT) and Silica Clotting Time (SCT). <i>Methods in Molecular Biology</i> , 2017, 1646, 177-183.	0.4	11
60	Changing Concepts of Cirrhotic Coagulopathy. <i>American Journal of Gastroenterology</i> , 2017, 112, 274-281.	0.2	149
61	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2017, 66, 248-250.	1.8	123
62	Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. <i>Endocrine</i> , 2017, 56, 298-307.	1.1	22
63	Detection of procoagulant imbalance. <i>Thrombosis and Haemostasis</i> , 2017, 117, 830-836.	1.8	35
64	Extracellular vesicle-driven information mediates the long-term effects of particulate matter exposure on coagulation and inflammation pathways. <i>Toxicology Letters</i> , 2016, 259, 143-150.	0.4	39
65	Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. <i>Digestive and Liver Disease</i> , 2016, 48, 1208-1213.	0.4	20
66	Resistance to thrombomodulin is associated with <i>de novo</i> portal vein thrombosis and low survival in patients with cirrhosis. <i>Liver International</i> , 2016, 36, 1322-1330.	1.9	51
67	How to report results of prothrombin and activated partial thromboplastin times. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 215-22.	1.4	19
68	Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban. <i>International Journal of Hematology</i> , 2016, 103, 165-172.	0.7	13
69	Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. <i>Thrombosis Research</i> , 2016, 137, 178-183.	0.8	141
70	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , 2016, 48, 455-467.	0.4	57
71	Thrombin Generation Assay and Its Application in the Clinical Laboratory. <i>Clinical Chemistry</i> , 2016, 62, 699-707.	1.5	241
72	Hemostasis abnormalities in cirrhosis. <i>Current Opinion in Hematology</i> , 2015, 22, 406-412.	1.2	55

#	ARTICLE	IF	CITATIONS
73	How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters. <i>Thrombosis Research</i> , 2015, 135, 1186-1190.	0.8	38
74	How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 265-73.	1.4	15
75	Coagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitis. <i>Journal of Hepatology</i> , 2015, 63, 277-278.	1.8	4
76	Periprocedural management of rivaroxaban-treated patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 685-691.	0.9	5
77	Liver Disease and Hemostatic (Dys)function. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 462-467.	1.5	41
78	A(nother) Test Meant to Fill the Gap between In Vivo and Ex Vivo Hemostasis. <i>Clinical Chemistry</i> , 2014, 60, 1137-1140.	1.5	5
79	Reply to: Is platelet transfusion necessary in cirrhotic patients with splenomegaly?. <i>Liver International</i> , 2014, 34, 478-479.	1.9	0
80	D-dimer testing for suspected venous thromboembolism in the emergency department. Consensus document of AcEMC, CISMEL, SIBioC, and SIMeL. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 621-8.	1.4	37
81	Laboratory tests during direct oral anticoagulant treatment. <i>Internal and Emergency Medicine</i> , 2014, 9, 903-905.	1.0	2
82	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014, 61, 148-154.	1.8	149
83	Statins decrease thrombin generation in patients with hypercholesterolemia. <i>European Journal of Internal Medicine</i> , 2014, 25, 449-451.	1.0	14
84	Comments on: Laboratory tests for the management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants: Proposals of the Working Group on Perioperative Haemostasis (GIHP). <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 345-346.	0.7	3
85	Thrombin generation in patients with idiopathic sudden sensorineural hearing loss. <i>Thrombosis Research</i> , 2014, 133, 1130-1134.	0.8	9
86	Should We Be Concerned About Coagulation in the Treatment of Acute Variceal Hemorrhage?. , 2014, , 203-210.		0
87	Results expression for tests used to measure the anticoagulant effect of new oral anticoagulants. <i>Thrombosis Journal</i> , 2013, 11, 9.	0.9	7
88	Global coagulation in myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2013, 92, 1633-1639.	0.8	26
89	Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. <i>Journal of Hepatology</i> , 2013, 59, 265-270.	1.8	146
90	The Laboratory and the New Oral Anticoagulants. <i>Clinical Chemistry</i> , 2013, 59, 353-362.	1.5	60

#	ARTICLE	IF	CITATIONS
91	Nontransfusal approach to increased platelet count in patients with cirrhosis and thrombocytopenia. <i>Hepatology</i> , 2013, 58, 1177-1180.	3.6	11
92	Anticoagulant Treatment With Rivaroxaban in Severe Protein S Deficiency. <i>Pediatrics</i> , 2013, 132, e1435-e1439.	1.0	33
93	Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. <i>Liver International</i> , 2013, 33, 362-367.	1.9	107
94	The laboratory and the direct oral anticoagulants. <i>Blood</i> , 2013, 121, 4032-4035.	0.6	97
95	Laboratory diagnostic outcome applying detection criteria recommended by the Scientific and Standardization Committee of the ISTH on Lupus Anticoagulant. <i>Thrombosis and Haemostasis</i> , 2013, 110, 46-52.	1.8	20
96	Liver disease, coagulopathies and transfusion therapy. <i>Blood Transfusion</i> , 2013, 11, 32-6.	0.3	26
97	Problems and Solutions for Testing Hemostasis Assays while Patients Are on Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 586-592.	1.5	12
98	To Mix or Not to Mix in Lupus Anticoagulant Testing? That is the Question. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 385-389.	1.5	35
99	The Long-Awaited Whole-Blood Thrombin Generation Test. <i>Clinical Chemistry</i> , 2012, 58, 1173-1175.	1.5	12
100	Interference of new oral anticoagulants with frequently used coagulation tests. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1501-3.	1.4	6
101	Position paper on laboratory testing for patients taking new oral anticoagulants. <i>Consensus Medicine</i> , 2012, 50, 2137-2140.	1.4	23
102	Circulating microparticles and risk of venous thromboembolism. <i>Thrombosis Research</i> , 2012, 129, 591-597.	0.8	92
103	Laboratory tests and the new oral anticoagulants. <i>Thrombosis Research</i> , 2012, 130, S95-S97.	0.8	11
104	Management of special conditions in patients on vitamin K antagonists. <i>Internal and Emergency Medicine</i> , 2012, 7, 407-413.	1.0	1
105	Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. <i>Internal and Emergency Medicine</i> , 2012, 7, 139-144.	1.0	96
106	Unbalanced oxidative status in idiopathic sudden sensorineural hearing loss. <i>European Archives of Oto-Rhino-Laryngology</i> , 2012, 269, 449-453.	0.8	70
107	Hemostatic defects in liver and renal dysfunction. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 168-173.	0.9	48
108	The Coagulopathy of Chronic Liver Disease. <i>New England Journal of Medicine</i> , 2011, 365, 147-156.	13.9	1,171

#	ARTICLE	IF	CITATIONS
109	Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability. <i>Thrombosis Research</i> , 2011, 127, 589-594.	0.8	8
110	Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test?. <i>Thrombosis and Haemostasis</i> , 2011, 105, 735-736.	1.8	18
111	Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation.. <i>Thrombosis and Haemostasis</i> , 2011, 106, 868-876.	1.8	158
112	Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 165-172.	1.0	129
113	The validity of the INR system for patients with liver disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 209-210.	1.0	4
114	d-Dimer Testing in Laboratory Practice. <i>Clinical Chemistry</i> , 2011, 57, 1256-1262.	1.5	157
115	Haemostasis Abnormalities in Chronic Liver Failure. , 2011, , 289-303.		7
116	Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. <i>Internal and Emergency Medicine</i> , 2010, 5, 7-12.	1.0	53
117	Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 215-219.	1.0	17
118	Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. <i>Hepatology</i> , 2010, 52, 249-255.	3.6	123
119	Pro-coagulant imbalance in patients with chronic liver disease. <i>Journal of Hepatology</i> , 2010, 53, 586-587.	1.8	8
120	The coagulopathy of chronic liver disease: Is there a causal relationship with bleeding? No. <i>European Journal of Internal Medicine</i> , 2010, 21, 65-69.	1.0	29
121	Increased thrombin generation in inflammatory bowel diseases. <i>Thrombosis Research</i> , 2010, 125, 278-282.	0.8	61
122	Laboratory Monitoring of Anticoagulation: Where Do We Stand?. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 034-041.	1.5	24
123	Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. <i>British Journal of Haematology</i> , 2009, 147, 77-82.	1.2	105
124	The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. <i>Thrombosis Research</i> , 2009, 124, 132-136.	0.8	155
125	A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. <i>Thrombosis Research</i> , 2009, 124, 137-143.	0.8	28
126	Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. <i>Journal of Hepatology</i> , 2009, 51, 288-295.	1.8	26

#	ARTICLE	IF	CITATIONS
127	An Imbalance of Pro- vs Anti-Coagulation Factors in Plasma From Patients With Cirrhosis. <i>Gastroenterology</i> , 2009, 137, 2105-2111.	0.6	472
128	Tests of Coagulation in Liver Disease. <i>Clinics in Liver Disease</i> , 2009, 13, 55-61.	1.0	47
129	Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. <i>Haematologica</i> , 2009, 94, 1520-1527.	1.7	74
130	How to implement the modified international normalized ratio for cirrhosis (INRliver) for model for end-stage liver disease calculation. <i>Hepatology</i> , 2008, 47, 1423-1424.	3.6	12
131	Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1534-1541.	1.9	57
132	Reply to: Endogenous heparinoids contribute to coagulopathy in patients with liver disease. <i>Journal of Hepatology</i> , 2008, 48, 372-373.	1.8	5
133	Laboratory Testing for Lupus Anticoagulants: Diagnostic Criteria and Use of Screening, Mixing, and Confirmatory Studies. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 373-379.	1.5	30
134	The History of Phenotypic Testing in Thrombosis and Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 585-592.	1.5	16
135	Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. <i>Haematologica</i> , 2008, 93, 900-907.	1.7	30
136	Normal thrombin generation in neonates in spite of prolonged conventional coagulation tests. <i>Haematologica</i> , 2008, 93, 1256-1259.	1.7	66
137	Hemostasis abnormalities in liver cirrhosis: myth or reality?. , 2008, 118, 445-8.		3
138	Laboratory Testing for Lupus Anticoagulants: A Review of Issues Affecting Results. <i>Clinical Chemistry</i> , 2007, 53, 1629-1635.	1.5	68
139	A Comparison of Lupus Anticoagulant-Positive Patients With Clinical Picture of Antiphospholipid Syndrome and Those Without. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, e309-10.	1.1	43
140	Interference of factor V Leiden on protein S activity: evaluation of a new prothrombin time-based assay. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 543-546.	0.5	4
141	Antiphospholipid antibody ELISAs: Survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti- β_2 -Glycoprotein I activity. <i>Thrombosis Research</i> , 2007, 120, 127-133.	0.8	77
142	The endogenous thrombin potential and the risk of venous thromboembolism. <i>Thrombosis Research</i> , 2007, 121, 353-359.	0.8	73
143	Abnormalities of hemostasis in chronic liver disease: Reappraisal of their clinical significance and need for clinical and laboratory research. <i>Journal of Hepatology</i> , 2007, 46, 727-733.	1.8	166
144	The international normalized ratio calibrated for cirrhosis (INRliver) normalizes prothrombin time results for model for end-stage liver disease calculation. <i>Hepatology</i> , 2007, 46, 520-527.	3.6	179

#	ARTICLE	IF	CITATIONS
145	d-Dimer Testing to Determine the Duration of Anticoagulation Therapy. <i>New England Journal of Medicine</i> , 2006, 355, 1780-1789.	13.9	593
146	Thrombin generation in patients with cirrhosis: The role of platelets. <i>Hepatology</i> , 2006, 44, 440-445.	3.6	347
147	A National Field Study of Quality Assessment of CoaguChek Point-of-Care Testing Prothrombin Time Monitors. <i>American Journal of Clinical Pathology</i> , 2006, 126, 756-761.	0.4	32
148	Thrombin Generation in Severe Hemophiliacs with Different Clinical Phenotype.. <i>Blood</i> , 2006, 108, 1000-1000.	0.6	1
149	Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. <i>Hepatology</i> , 2005, 41, 553-558.	3.6	617
150	Issues Concerning the Laboratory Investigation of Inherited Thrombophilia. <i>Molecular Diagnosis and Therapy</i> , 2005, 9, 181-186.	1.3	13
151	A Review of the Clinical and Diagnostic Utility of Laboratory Tests for the Detection of Congenital Thrombophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 25-32.	1.5	36
152	Performance of Clinical Laboratories for DNA Analyses to Detect Thrombophilia Mutations. <i>Clinical Chemistry</i> , 2005, 51, 1310-1311.	1.5	13
153	Lupus Anticoagulants and Their Relationship with the Inhibitors against Coagulation Factor VIII: Considerations on the Differentiation between the 2 Circulating Anticoagulants. <i>Clinical Chemistry</i> , 2005, 51, 1883-1885.	1.5	44
154	Issues Concerning the Laboratory Investigation of Inherited Thrombophilia. , 2005, 9, 181.		2
155	European Concerted Action on Anticoagulation. Quality Assessment of the CoaguChek Mini and TAS PT-NC Point-of-Care Whole-Blood Prothrombin Time Monitors. <i>Clinical Chemistry</i> , 2004, 50, 537-544.	1.5	20
156	Standardization of the endogenous thrombin potential measurement: how to minimize the effect of residual platelets in stored plasma. <i>British Journal of Haematology</i> , 2004, 124, 355-357.	1.2	19
157	Quality assurance program for whole blood prothrombin timeâ€™international normalized ratio point-of-care monitors used for patient self-testing to control oral anticoagulation. <i>Thrombosis Research</i> , 2004, 113, 35-40.	0.8	17
158	Prothrombin time international normalized ratio monitoring by self-testing. <i>Current Opinion in Hematology</i> , 2004, 11, 141-145.	1.2	11
159	A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. <i>Blood</i> , 2004, 104, 3631-3634.	0.6	179
160	Standardization of activated protein C resistance testing: effect of residual platelets in frozen plasmas assessed by commercial and home-made methods. <i>British Journal of Haematology</i> , 2003, 120, 825-828.	1.2	8
161	Lupus Anticoagulant (LA) Testing: Performance of Clinical Laboratories Assessed by a National Survey Using Lyophilized Affinity-purified Immunoglobulin with LA Activity. <i>Clinical Chemistry</i> , 2003, 49, 1608-1614.	1.5	70
162	International Sensitivity Index Calibration of the Near-Patient Testing Prothrombin Time Monitor, ProTime. <i>American Journal of Clinical Pathology</i> , 2003, 119, 241-245.	0.4	9

#	ARTICLE	IF	CITATIONS
163	Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods. <i>BMJ: British Medical Journal</i> , 2003, 327, 30-0.	2.4	40
164	European Concerted Action on Anticoagulation. <i>American Journal of Clinical Pathology</i> , 2003, 119, 232-240.	0.4	21
165	Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. <i>Haematologica</i> , 2003, 88, 547-54.	1.7	140
166	Levels of coagulation factors and venous thromboembolism. <i>Haematologica</i> , 2003, 88, 705-11.	1.7	27
167	How to evaluate the influence of blood collection systems on the international sensitivity index. Protocol applied to two new evacuated tubes and eight coagulometer/thromboplastin combinations. <i>Thrombosis Research</i> , 2002, 108, 85-89.	0.8	27
168	European Concerted Action on Anticoagulation. Evaluation of a Method for International Sensitivity Index Calibration of Two Point-of-Care Prothrombin Time (PT) Monitoring Systems (CoaguChek Mini) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 1672-1680.	1.5	18
169	European Concerted Action on Anticoagulation. Use of Plasma Samples to Derive International Sensitivity Index for Whole-Blood Prothrombin Time Monitors. <i>Clinical Chemistry</i> , 2002, 48, 255-260.	1.5	24
170	Laboratory Diagnosis of Lupus Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2002, 87, 854-858.	1.8	15
171	Laboratory diagnosis of thrombophilic states: where do we stand?. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002, 32, 245-248.	0.5	8
172	Laboratory Diagnosis of Lupus Anticoagulants for Patients on Oral Anticoagulant Treatment. <i>Thrombosis and Haemostasis</i> , 2002, 88, 583-586.	1.8	64
173	Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations – A Cause for Concern. <i>Thrombosis and Haemostasis</i> , 2002, 88, 690-691.	1.8	41
174	Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. <i>Thrombosis and Haemostasis</i> , 2002, 88, 583-6.	1.8	17
175	Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations—a cause for concern. <i>Thrombosis and Haemostasis</i> , 2002, 88, 690-1.	1.8	6
176	Multicenter Study of Homocysteine Measurement – Performance Characteristics of Different Methods, Influence of Standards on Interlaboratory Agreement of Results. <i>Thrombosis and Haemostasis</i> , 2001, 85, 291-295.	1.8	53
177	Laboratory Investigation of Thrombophilia. <i>Clinical Chemistry</i> , 2001, 47, 1597-1606.	1.5	116
178	Near-patient testing devices to monitor oral anticoagulant therapy. <i>British Journal of Haematology</i> , 2001, 113, 847-852.	1.2	41
179	Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. <i>British Journal of Haematology</i> , 2001, 115, 672-678.	1.2	84
180	Hyperprothrombinemia may result in acquired activated protein C resistance. <i>Blood</i> , 2000, 96, 3295-3296.	0.6	28

#	ARTICLE	IF	CITATIONS
181	Alpha2-Macroglobulin Levels Are High in Adult Patients with Congenital Antithrombin Deficiency. <i>Thrombosis Research</i> , 2000, 98, 117-122.	0.8	8
182	Calibration of Local Systems with Lyophilized Calibrant Plasmas Improves the Interlaboratory Variability of the INR in the Italian External Quality Assessment Scheme. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1621-1626.	1.8	25
183	Standardization of the APC Resistance Test. Effects of Normalization of Results by Means of Pooled Normal Plasma. <i>Thrombosis and Haemostasis</i> , 1998, 79, 564-566.	1.8	16
184	Assessment of the Influence of Citrate Concentration on the International Normalized Ratio (INR) Determined with Twelve Reagent-instrument Combinations. <i>Thrombosis and Haemostasis</i> , 1998, 80, 258-262.	1.8	40
185	International Collaborative Study for the Calibration of a Proposed Reference Preparation for Thromboplastin, Human Recombinant, Plain. <i>Thrombosis and Haemostasis</i> , 1998, 79, 439-443.	1.8	54
186	Screening for the FV: Q506 Mutation – Evaluation of Thirteen Plasma-based Methods for their Diagnostic Efficacy in Comparison with DNA Analysis. <i>Thrombosis and Haemostasis</i> , 1997, 77, 436-439.	1.8	55
187	Determination of the International Sensitivity Index of a New Near-Patient Testing Device to Monitor Oral Anticoagulant Therapy. <i>Thrombosis and Haemostasis</i> , 1997, 78, 855-858.	1.8	25
188	Are Capillary Whole Blood Coagulation Monitors Suitable for the Control of Oral Anticoagulant Treatment by the International Normalized Ratio?. <i>Thrombosis and Haemostasis</i> , 1993, 70, 0921-0924.	1.8	93
189	Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. <i>Thrombosis Research</i> , 1992, 67, 355-365.	0.8	54
190	Recombinant Tissue Factor as Substitute for Conventional Thromboplastin in the Prothrombin Time Test. <i>Thrombosis and Haemostasis</i> , 1992, 67, 042-045.	1.8	19
191	Laboratory Screening of Inherited Thrombotic Syndromes. <i>Thrombosis and Haemostasis</i> , 1987, 57, 247-251.	1.8	67
192	Factor VIII Activity as Measured by an Amidolytic Assay Compared with a One-Stage Clotting Assay. <i>American Journal of Clinical Pathology</i> , 1986, 86, 341-344.	0.4	10